Published April 28, 2026 | Version v1
Preprint Open

Metformin Repurposing for FMR1-Associated Metabolic Dysfunction

Authors/Creators

  • 1. MedicOath

Description

Clinical trial NCT03862950 completed testing metformin in FXS patients. FAERS data shows hydroxychloroquine (6 reports) and sulfasalazine (7 reports) co-reported with FXS, both drugs affecting similar metabolic/inflammatory pathways as metformin. Metformin may restore mTOR signaling and protein synthesis balance disrupted in FXS.

Notes

IPFS: QmcQuuzCbGECNJMEpc76PGiaFM9sBNA17sMhGj1aJDddSM. TX: 0x18eebe7347772346a70b001f3f8a2f82bdb01c691ed900f46320898ffaf42e65. CC0.

Files

hypothesis.json

Files (345 Bytes)

Name Size Download all
md5:553583178456ba6fab38f0d7dce3c196
345 Bytes Preview Download